General
Preferred name
FUNAPIDE
Synonyms
XEN-402 ()
TV 45070 ()
XEN402 ()
XEN-401-S ()
TV-45070 ()
XPF-002 ()
P&D ID
PD058988
CAS
1259933-16-8
Tags
available
drug candidate
Drug indication
Osteoarthritis
Vasodilatation of extremities
Pain
Drug Status
investigational
Max Phase
Phase 2
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Funapide (XEN-402) is a NaV1.7 channel inhibitor that is proposed for analgesic activity .
(GtoPdb)
DESCRIPTION
Funapide is a Nav1.7 and Nav1.8 voltage-gated sodium channel inhibitor under the development by Xenon Pharmaceuticals and Teva Pharmaceutical Industries. It is applicated for the treatment of a variety of chronic painconditions, including osteoarthritis, neuropathic pain, postherpetic, neuralgia, erythromelalgia and dental pain. In July 2014, Funapide has reached phase IIb clinical trials.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
8
BOC Sciences Bioactive Compounds
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugMAP
Guide to Pharmacology
MedChem Express Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
22
Molecular Weight
429.08
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
0
Rotatable Bonds
2
Ring Count
6
Aromatic Ring Count
3
cLogP
4.25
TPSA
61.14
Fraction CSP3
0.23
Chiral centers
1.0
Largest ring
6.0
QED
0.61
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
Sodium Channel blocker
VGSC Target
Nav1.2
Nav1.5
Nav1.6
Nav1.8
Pathway
Membrane Transporter/Ion Channel
Target
Sodium Channel
Solubility
Soluble in DMSO
Source data
